From Name:
From Email:
To Name:
To Email:

Optional Message:

FDA approves targeted therapy combo for leukemia

from Cancer Health

The Food and Drug Administration approved a combination of two targeted therapies, Imbruvica (ibrutinib) and Gazyva (obinutuzumab), as the first non-chemotherapy initial regimen for people with chronic lymphocytic leukemia and the similar blood cancer small lymphocytic lymphoma. The approval was based on a study showing that the combination significantly improved progression-free survival compared with standard therapy. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063